Practical application of natriuretic peptides in paediatric cardiology

Cardiology in the Young

Volumn 20, Issue 4, 2010, Pages 353-363

  Smith, Julie ^a   Goetze, Jens P ^a   Andersen, Claus B ^a   Vejlstrup, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

B type natriuretic peptide; congenital cardiac disease; heart transplantation; N terminal pro B type natriuretic peptide; reference intervals

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; BIOLOGICAL MARKER;

CARDIAC GRAFT REJECTION; FALLOT TETRALOGY; HEART ATRIUM SEPTUM DEFECT; HEART TRANSPLANTATION; HUMAN; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PEDIATRIC CARDIOLOGY; PREMATURITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PULMONARY VALVE INSUFFICIENCY; REVIEW; RISK FACTOR; SEX DIFFERENCE; ADOLESCENT; CARDIOLOGY; CHILD; HEART DISEASE; INFANT; METABOLISM; NEWBORN; PEDIATRICS; PREDICTION AND FORECASTING; PRESCHOOL CHILD;

ADOLESCENT; BIOLOGICAL MARKERS; CARDIOLOGY; CHILD; CHILD, PRESCHOOL; HEART DISEASES; HUMANS; INFANT; INFANT, NEWBORN; NATRIURETIC PEPTIDES; PEDIATRICS; PREDICTIVE VALUE OF TESTS;

EID: 78349259373     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951110000211     Document Type: Review

References (91)

1. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003; 45: 249-254.
2. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci. 28: 89-94, 1981. J Am Soc Nephrol 2001; 12: 403-409.
3. Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alphahANP). Biochem Biophys Res Commun 1984; 118: 131-139.
4. Sudoh T, Maekawa K, Kojima M, et al. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 1989; 159: 1427-1434.
5. Ogawa Y, Itoh H, Yoshitake Y, et al. Molecular cloning and chromosomal assignment of the mouse C-type natriuretic peptide (CNP) gene (Nppc): Comparison with the human CNP gene (NPPC). Genomics 1994; 24: 383-387.
6. Tamura N, Ogawa Y, Yasoda A, et al. Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes. J Mol Cell Cardiol 1996; 28: 1811-1815.
7. Nielsen SJ, Gotze JP, Jensen HL, Rehfeld JF. ProCNP and CNP are expressed primarily in male genital organs. Regul Pept 2008; 146: 204-212.
8. Tsuchimochi H, Kurimoto F, Ieki K, et al. Atrial natriuretic peptide distribution in fetal and failed adult human hearts. Circulation 1988; 78: 920-927.
9. Takahashi T, Allen PD, Izumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(21)-ATPase gene. Circ Res 1992; 71: 9-17.
10. Cameron VA, Aitken GD, Ellmers LJ, Kennedy MA, Espiner EA. The sites of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal development: Temporal changes in embryos and placenta. Endocrinology 1996; 137: 817-824.
11. Mantymaa P, Vuolteenaho O, Marttila M, Ruskoaho H. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 1993; 133: 1470-1473.
12. Kinnunen P, Vuolteenaho O, Uusimaa P, Ruskoaho H. Passive mechanical stretch releases atrial natriuretic peptide from rat ventricular myocardium. Circ Res 1992; 70: 1244-1253.
13. Liang F, Wu J, Garami M, Gardner DG. Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes. J Biol Chem 1997; 272: 28050-28056.
14. Hosoda K, Nakao K, Mukoyama M, et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 1991; 17: 1152-1155.
15. Nakao K, Mukoyama M, Hosoda K, et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991; 69: 1500-1506.
16. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
17. Tulevski II, Groenink M, van Der Wall EE, et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: Correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001; 86: 27-30.
18. Weidemann A, Klanke B, Wagner M, et al. Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J 2008; 409: 233-242.
19. Khan AR, Birbach M, Cohen MS, et al. Chronic hypoxemia increases ventricular brain natriuretic peptide precursors in neonatal swine. Ann Thorac Surg 2008; 85: 618-623.
20. Goetze JP, Gore A, Moller CH, et al. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18: 1928-1930.
21. Rankin AJ, Courneya CA, Wilson N, Ledsome JR. Tachycardia releases atrial natriuretic peptide in the anesthetized rabbit. Life Sci 1986; 38: 1951-1957.
22. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91: 1127-1134.
23. Walther T, Klostermann K, Heringer-Walther S, et al. Fibrosis rather than blood pressure determines cardiac BNP expression in mice. Regul Pept 2003; 116: 95-100.
24. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43: 1590-1595.
25. Jensen KT, Carstens J, Ivarsen P, Pedersen EB. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997; 57: 529-540.
26. Piuhola J, Szokodi I, Ruskoaho H. Endothelin-1 and angiotensin II contribute to BNP but not c-fos gene expression response to elevated load in isolated mice hearts. Biochim Biophys Acta 2007; 1772: 338-344.
27. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length. Circulation 2000; 102: 3074-3079.
28. Emdin M, Passino C, Prontera C, et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 2004; 42: 627-636.
29. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91-96.
30. Misono KS, Grammer RT, Fukumi H, Inagami T. Rat atrial natriuretic factor: Isolation, structure and biological activities of four major peptides. Biochem Biophys Res Commun 1984; 123: 444-451.
31. Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998; 21: 170-179.
32. Buckley MG, Sagnella GA, Markandu ND, Singer DR, MacGregor GA. Immunoreactive N-terminal pro-atrial natriuretic peptide in human plasma: Plasma levels and comparisons with alpha-human atrial natriuretic peptide in normal subjects, patients with essential hypertension, cardiac transplant and chronic renal failure. Clin Sci (Lond) 1989; 77: 573-579.
33. Buckley MG, Sethi D, Markandu ND, et al. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysisdependent chronic renal failure. Clin Sci (Lond) 1992; 83: 437-444.
34. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-208.
35. Goetze JP, Dahlstrom U, Rehfeld JF, Alehagen U. Impact of epitope specificity and precursor maturation in pro-B-type natriuretic peptide measurement. Clin Chem 2008; 54: 1780-1787.
36. Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007; 49: 1114-1119.
37. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007; 49: 1193-1202.
38. Hawkridge AM, Heublein DM, Bergen III HR, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005; 102: 17442-17447.
39. Seferian KR, Tamm NN, Semenov AG, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007; 53: 866-873.
40. Seferian KR, Tamm NN, Semenov AG, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008; 54: 866-873.
41. Hammerer-Lercher A, Puschendorf B, Sommer R, et al. Natriuretic peptides correlate between newborn twins but not between twins and their mothers. Clin Chim Acta 2007; 377: 279-280.
42. Hammerer-Lercher A, Mair J, Tews G, Puschendorf B, Sommer R. N-terminal pro-B-type natriuretic peptide concentrations are markedly higher in the umbilical cord blood of newborns than in their mothers. Clin Chem 2005; 51: 913-915.
43. Bakker J, Gies I, Slavenburg B, et al. Reference values for N-terminal pro-B-type natriuretic peptide in umbilical cord blood. Clin Chem 2004; 50: 2465.
44. Bar-Oz B, Lev-Sagie A, Arad I, Salpeter L, Nir A. N-terminal pro-B-type natriuretic peptide concentrations in mothers just before delivery, in cord blood, and in newborns. Clin Chem 2005; 51: 926-927.
45. Mir TS, Laux R, Hellwege HH, et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: Marked and rapid increase after birth. Pediatrics 2003; 112: 896-899.
46. Nir A, Bar-Oz B, Perles Z, et al. N-terminal pro-B-type natriuretic peptide: Reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004; 93: 603-607.
47. Rauh M, Koch A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem 2003; 49: 1563-1564.
48. Schwachtgen L, Herrmann M, Georg T, et al. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol 2005; 94: 399-404.
49. Albers S, Mir TS, Haddad M, Laer S. N-Terminal pro-brain natriuretic peptide: Normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 2006; 44: 80-85.
50. Cohen S, Springer C, Avital A, et al. Amino-terminal pro-braintype natriuretic peptide: Heart or lung disease in pediatric respiratory distress? Pediatrics 2005; 115: 1347-1350.
51. Eerola A, Jokinen E, Boldt T, Pihkala J. The influence of percutaneous closure of patent ductus arteriosus on left ventricular size and function: A prospective study using two- and threedimensional echocardiography and measurements of serum natriuretic peptides. J Am Coll Cardiol 2006; 47: 1060-1066.
52. Eerola A, Pihkala JI, Boldt T, et al. Hemodynamic improvement is faster after percutaneous ASD closure than after surgery. Catheter Cardiovasc Interv 2007; 69: 432-441.
53. Geiger R, Hammerer-Lercher A, Url C, et al. NT-proBNP concentrations indicate cardiac disease in pediatric patients. Int J Cardiol 2007; 123: 63-65.
54. Koch AM, Rauh M, Zink S, Singer H. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatr 2006; 95: 805-809.
55. Mir TS, Flato M, Falkenberg J, et al. Plasma concentrations of Nterminal brain natriuretic peptide in healthy children, adolescents, and young adults: Effect of age and gender. Pediatr Cardiol 2006; 27: 73-77.
56. Hammerer-Lercher A, Geiger R, Mair J, et al. Utility of Nterminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem 2006; 52: 1415-1419.
57. Ko HK, Lee JH, Choi BM, et al. Utility of the rapid B-type natriuretic peptide assay for detection of cardiovascular problems in newborn infants with respiratory difficulties. Neonatology 2008; 94: 16-21.
58. Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114: 1297-1304.
59. Mannarino S, Ciardelli L, Garofoli F, et al. Correlation between cord blood, perinatal BNP values and echocardiographic parameters in healthy Italian newborns. Early Hum Dev 2009; 85: 13-17.
60. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003; 89: 875-878.
61. Kunii Y, Kamada M, Ohtsuki S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003; 57: 191-197.
62. Holmgren D, Westerlind A, Lundberg PA, Wahlander H. Increased plasma levels of natriuretic peptide type B and A in children with congenital heart defects with left compared with right ventricular volume overload or pressure overload. Clin Physiol Funct Imaging 2005; 25: 263-269.
63. Muta H, Ishii M, Maeno Y, Akagi T, Kato H. Quantitative evaluation of the changes in plasma concentrations of cardiac natriuretic peptide before and after transcatheter closure of atrial septal defect. Acta Paediatr 2002; 91: 649-652.
64. Takeuchi D, Saji T, Takatsuki S, Fujiwara M. Abnormal tissue doppler images are associated with elevated plasma brain natriuretic peptide and increased oxidative stress in acute Kawasaki disease. Circ J 2007; 71: 357-362.
65. Alehagen U, Goetze JP, Dahlstrom U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta 2007; 382: 8-14.
66. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002; 40: 976-982.
67. Kroll MH, Twomey PJ, Srisawasdi P. Using the singlecompartment ratio model to calculate half-life, NT-proBNP as an example. Clin Chim Acta 2007; 380: 197-202.
68. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: Observations from the Dallas Heart Study. J Am Coll Cardiol 2007; 49: 109-116.
69. Lin NC, Landt ML, Trinkaus KM, et al. Relation of age, severity of illness, and hemodynamics with brain natriuretic peptide levels in patients ,20 years of age with heart disease. Am J Cardiol 2005; 96: 847-850.
70. Ozhan H, Albayrak S, Uzun H, et al. Correlation of plasma B-type natriuretic peptide with shunt severity in patients with atrial or ventricular septal defect. Pediatr Cardiol 2007; 28: 272-275.
71. Mir TS, Falkenberg J, Friedrich B, et al. Levels of brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease. Cardiol Young 2005; 15: 396-401.
72. Czernik C, Lemmer J, Metze B, et al. B-type natriuretic peptide to predict ductus intervention in infants ,28 weeks. Pediatr Res 2008; 64: 286-290.
73. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005; 115: E255-e261.
74. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005; 147: 38-42.
75. Farombi-Oghuvbu IO, Matthews T, Mayne PD, Guerin H, Corcoran D. N-terminal pro-B-type natriuretic peptide: A measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008; 93: F257-F260.
76. Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002; 103: 75-77.
77. da Graca RL, Hassinger DC, Flynn PA, et al. Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics 2006; 117: 2183-2189.
78. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006; 27: 861-866.
79. Cheung EW, Lam WW, Chiu CS, et al. Plasma brain natriuretic peptide levels, right ventricular volume overload and exercise capacity in adolescents after surgical repair of tetralogy of Fallot. Int J Cardiol 2007; 121: 155-162.
80. Khositseth A, Manop J, Khowsathit P, et al. N-terminal probrain natriuretic peptide as a marker in follow-up patients with tetralogy of Fallot after total correction. Pediatr Cardiol 2007; 28: 333-338.
81. Lindblade CL, Chun DS, Darragh RK, et al. Value of plasma B-type natriuretic peptide as a marker for rejection in pediatric heart transplant recipients. Am J Cardiol 2005; 95: 909-911.
82. Claudius I, Lan YT, Chang RK, Wetzel GT, Alejos J. Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients. Am J Cardiol 2003; 92: 1368-1370.
83. Lan YT, Chang RK, Alejos JC, Burch C, Wetzel GT. B-type natriuretic peptide in children after cardiac transplantation. J Heart Lung Transplant 2004; 23: 558-563.
84. Rossano JW, Denfield SW, Kim JJ, et al. B-type natriuretic peptide is a sensitive screening test for acute rejection in pediatric heart transplant patients. J Heart Lung Transplant 2008; 27: 649-654.
85. Geiger M, Harake D, Halnon N, Alejos JC, Levi DS. Screening for rejection in symptomatic pediatric heart transplant recipients: The sensitivity of BNP. Pediatr Transplant 2008; 12: 563-569.
86. Flynn TG, de Bold ML, de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 1983; 117: 859-865.
87. Kangawa K, Fukuda A, Matsuo H. Structural identification of beta- and gamma-human atrial natriuretic polypeptides. Nature 1985; 313: 397-400.
88. Kambayashi Y, Nakao K, Mukoyama M, et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett 1990; 259: 341-345.
89. Hino J, Tateyama H, Minamino N, Kangawa K, Matsuo H. Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun 1990; 167: 693-700.
90. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000; 97: 8525-8529.
91. Brandt I, Lambeir AM, Ketelslegers JM, et al. Dipeptidylpeptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006; 52: 82-87.